[6-K] MediWound Ltd. Current Report (Foreign Issuer)

Rhea-AI Filing Summary

MediWound Ltd. announced a $30 million registered direct offering of ordinary shares. The disclosure in this Form 6-K references a press release titled "MediWound Announces $30 Million Registered Direct Offering of Ordinary Shares." The filing provides the existence and size of the offering but does not include pricing, number of shares, underwriters, or stated use of proceeds within the text provided. Additional offering particulars and material terms are not present in the supplied content.

Positive

• Company disclosed a $30 million capital raise via a registered direct offering, indicating access to additional financing.
• Use of a registered offering suggests the shares are sold under an existing registration, which can streamline the sale process to investors.

Negative

• Key transaction details are missing from the supplied content: offering price, number of shares, investor identities, and intended use of proceeds are not included.
• Potential dilution considerations cannot be quantified because the share count and pricing are not disclosed in the text provided.

Insights

Securities Analyst

TL;DR: Company disclosed a $30M registered direct offering; key terms are missing from the provided text.

The filing confirms a capital raise via a registered direct offering totaling $30 million in ordinary shares. Registered direct offerings typically allow a company to sell shares directly to investors using a registration statement, which can expedite access to capital. Because the supplied content lacks pricing, share count, investor identity, and use-of-proceeds detail, assessing dilution, timing, or balance-sheet impact is not possible from this excerpt alone.

Corporate Finance Specialist

TL;DR: A $30M equity raise is disclosed; without transaction mechanics, material impact cannot be determined from this text.

The announcement signals an equity financing event of $30 million. Such financings can strengthen liquidity or fund operations, but the filing excerpt does not state whether the proceeds will repay debt, fund R&D, or provide working capital. The absence of transactional terms prevents a clear assessment of whether the offering is accretive, dilutive, or aligned with strategic objectives.

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C.  20549
______________________

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

Pursuant to Rule 13a-16 or 15d-16 of the
Securities Exchange Act of 1934

For the month of September 2025

Commission File Number: 001-36349

MediWound Ltd.
(Translation of registrant’s name into English)

42 Hayarkon Street

Yavne, 8122745 Israel

 (Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒          Form 40-F ☐

EXPLANATORY NOTE

On September 29, 2025, MediWound Ltd. (the “Company”) issued a press release entitled “MediWound Announces $30 Million Registered Direct Offering of Ordinary Shares”. A copy of this press release is attached to this Report of Foreign Private Issuer on Form 6-K (this “Form 6-K”) as Exhibit 99.1.

The content of this report on Form 6-K (including the information contained in Exhibit 99.1), is hereby incorporated by reference into the Company’s Registration Statements on Form S-8 filed with the SEC on April 28, 2014, March 24, 2016, March 19, 2018, March 25, 2019, February 25, 2020, May 15, 2021 August 9, 2022, August 15, 2023, and March 19, 2025 (Registration Nos. No. 333-195517, 333-210375, 333-223767, 333-230487, 333-236635, 333-255784, 333-266697, 333-273997 and 333-285897, respectively) and on Form F-3 filed with the SEC on March 31, 2023,  August 29, 2024 and March 19, 2025 (Registration Nos. 333-268297, 333-281843 and 333-285908, respectively.

2

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: September 29, 2025 MEDIWOUND LTD.   By:  /s/ Hani Luxenburg  
Name:  Hani Luxenburg Title:    Chief Financial Officer

3

EXHIBIT INDEX

The following exhibit is filed as part of this Form 6-K:

Exhibit Description

99.1 Press release dated September 29, 2025 entitled “MediWound Announces $30 Million Registered Direct Offering of Ordinary Shares”.

4

FAQ

What did MediWound (MDWD) announce in this Form 6-K?

The company announced a $30 million registered direct offering of ordinary shares as referenced by a press release.

Does the filing specify the price or number of shares in the $30M offering?

No. The provided content does not include the offering price, the number of shares to be sold, or the identity of purchasers.

Is the intended use of proceeds for the $30 million offering disclosed?

No. The supplied excerpt does not state how MediWound plans to use the proceeds from the offering.

Was the $30M offering registered or private?

The press release title and filing describe it as a registered direct offering, indicating it is being conducted under a registration.

Where can I find more details about this offering for MDWD?

The Form 6-K references a press release titled "MediWound Announces $30 Million Registered Direct Offering of Ordinary Shares." The provided content does not include further transaction terms, so consult the full press release or subsequent SEC filings for complete details.